|Dr. Jason Loveridge B.Sc, B.Sc., FRSM, Ph.D.||Chairman of Management Board, CEO & MD||519k||N/A||N/A|
|Ms. Anna Niedl Ph.D.||Corp. Communications & Investor Relations Officer||N/A||N/A||N/A|
|Dr. Susanne Danhauser-Riedl M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Larissa Stuttem||Team Assistant||N/A||N/A||N/A|
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs in Germany. Its products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase Ib/II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. The company also out-licenses its products to pharma and biotech companies for the treatment of cancer. It has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. The company was founded in 1997 and is headquartered in Planegg, Germany.
4SC AG’s ISS governance QualityScore as of 1 October 2022 is 8. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 8; Compensation: 8.